Abstract:Abstract Patients diagnosed with early stage head and neck squamous cell carcinoma (HNSCC) have a high risk of developing second primary tumors (SPT) or recurrence following curative purpose therapy. To prevent these occurrences, several chemoprevention agents have been developed, including 13-cis-retinoid acid (13-cRA). However, results from clinical trials have remained inconclusive and suggest that biomarkers may be needed to select patients who will receive benefit from therapy. The mTOR signaling pathway plays a major role in the regulation of cell growth, cell survival, and apoptosis. We hypothesized that genetic variation in this pathway may serve as prognostic factors for the development of SPT/recurrence and affect response to chemoprevention therapy. We genotyped 137 SNPs from genes within this pathway in 450 HNSCC patients who received 13-cRA or placebo as part of the Retinoid Head and Neck Second Primary Trial. Genotypes were then analyzed for association with risk of SPT/recurrence to identify biomarkers for prognosis and treatment response. Twenty-two genetic loci were significant prognostic factors for SPT/recurrence in the placebo treatment group. Of these, nine were SNPs within the tuberous sclerosis 1 (TSC1) gene and most often resulted in an increased SPT/recurrence risk for the majority of patients carrying the wild-type genotype. Two of these alleles (rs4962225 and rs7035940) were in strong linkage disequilibrium and resulted in a high risk of SPT/recurrence (HR: 1.92, 95% CI: 1.15–3.23) and a significant 18 month survival disadvantage (Log-rank P = 0.026) in those carrying the wild-type genotype. These results indicate that this locus may be a potential target for chemoprevention. Intriguingly, although 13-cRA did not show a reduction in SPT/recurrence risk overall, response to this therapy was significantly different depending on the patient's genetic background for these potential targets. A significant modulation of SPT/recurrence risk in those who received 13-cRA was observed for seven of the prognostic TSC1 SNPs. The majority of the population with the wild-type genotype were conferred the protective effect of 13-cRA, indicating that the high-risk group for SPT/recurrence were being effectively treated by this chemoprevention intervention. Individuals carrying the wild-type genotype for either TSC1 rs4962225 or rs7035940 were at a 43% reduced risk (95% CI: 0.37–0.88). However those who carried at least one variant allele did not receive the benefit of 13-cRA treatment and were at an increased risk (HR: 1.91, 95% CI: 1.10–3.32). These results indicate that genetic variation within the mTOR pathway, particularly TSC1, could potentially be used to better identify patients who are at high-risk of SPT/recurrence and also those who are candidates for chemoprevention therapy based on their favorable genetic background. Citation Information: Cancer Prev Res 2010;3(1 Suppl):B94.

Supplementary Table 1 from Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention

Predictive Biomarkers and Personalized Medicine Genetic Variants in the PI 3 K / PTEN / AKT / mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor / Recurrence Risk and Response to Retinoid Chemoprevention

Supplementary Table 2 from Inherited Variants in Mitochondrial Biogenesis Genes May Influence Epithelial Ovarian Cancer Risk

Abstract B94: Pharmacogenetics of Retinoid Chemoprevention in Head and Neck Cancer Patients: Modulation of Response by Common Genetic Variation in the Mtor Signaling Pathway

Global Assessment of Genetic Variation Influencing Response to Retinoid Chemoprevention in Head and Neck Cancer Patients

Supplementary Table 1-3 from MicroRNA-Related Genetic Variants Associated with Clinical Outcomes in Early-Stage Non–Small Cell Lung Cancer Patients

Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated with Clinical Outcomes in Esophageal Cancer Patients Treated with Chemoradiotherapy

Supplementary Table S3 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation

Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.

Supplementary Figures 1 - 12, Tables 1 - 5 from Favorable Prognostic Impact in Loss of <i>tp53</i> and <i>pik3ca</i> Mutations after Neoadjuvant Chemotherapy in Breast Cancer

Supplementary Table S6 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Tumor Genomics and the Association with Survival in Recurrent/metastatic Head and Neck Cancer Patients

Abstract PR-03: Genetic Variations in Microrna Biogenesis Genes As Predictors for Risk of Second Primary Tumor (SPT) And/or Recurrence in Patients with Early-Stage Head and Neck Cancer

Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

PI3K/PTEN/AKT/mTOR Pathway Genetic Variation Predicts Toxicity and Distant Progression in Lung Cancer Patients Receiving Platinum-Based Chemotherapy.

Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Supplementary Figure 3 from Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Data from Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer

Supplementary Figure 3 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 2 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib